Search
Trestolone
go.drugbank.com/drugs/DB05830InvestigationalTrestolone (7α-methyl-19-nortestosterone) is a synthetic androgen developed by the Population Council as a potential candidate drug for use in hormonal male contraceptive methods.
Talimogene laherparepvec
go.drugbank.com/drugs/DB13896ApprovedInvestigationalIt was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221].
Larazotide
go.drugbank.com/drugs/DB05645InvestigationalAn octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.
Gallium Ga-68 gozetotide
go.drugbank.com/drugs/DB16019ApprovedInvestigational[L43542] In December of the same year, the drug was fully authorized by the EMA.[L44682] In Octer 2022, Ga-68 PSMA-11 was approved by Health Canada for diagnostic use in men with prostate cancer. … [L27006] On December 1, 2020, Ga-68 PSMA-11 was approved by the FDA as the first molecular-targeted drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … _ (Avatrombopag) is the first orally administered treatment option for patients with chronic liver disease, allowing a large population of patients to avoid a platelet transfusion before a procedure by
Cholecystokinin
go.drugbank.com/drugs/DB08862ApprovedInvestigationalWithdrawnNormally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form. … Cholecystokinin, previously called _pancreozymin_, is synthesized and secreted by enteroendocrine cells in the duodenum (the first portion of the small intestine) and leads to the release of bile and digestive
Sacubitril
go.drugbank.com/drugs/DB09292ApprovedInvestigationalIt was approved by the FDA after being given the status of priority review for on July 7, 2015.
NOX-100
go.drugbank.com/drugs/DB05799InvestigationalNOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.
HGS-TR2J
go.drugbank.com/drugs/DB05895ExperimentalIt is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
Selenomethionine
go.drugbank.com/drugs/DB11142ApprovedInvestigationalSelenomethionine is a naturally occuring amino acid in some plant materials such as cereal grains, soybeans and enriched yeast but it cannot be synthesized from animals or humans.